Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over

  • Technology appraisal guidance
  • TA1054
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence